Pharmaceuticals, Biotechnology and Life Sciences
Washington ordered a vaccine that doesn’t exist. Here’s what it would actually take to build it.
Trump’s MMR executive order is being covered as a political story. The more consequential question is a manufacturing one — and the answer from the only company that matters is: ten years, maybe more.
The movement that spent years insisting vaccines were dangerous, unnecessary, and a tool of government overreach just got an unusual…
A five-minute pre-surgical procedure using light is about to face its biggest test — and the clinical trial metrics, according to the company, are unusually clean.
GlaxoSmithKline has entered into an agreement to acquire Canadian clinical-stage biotech 35Pharma Inc. for $950 million in cash, expanding its respiratory and cardiovascular pipeline, according to regulatory filings and the company’s announcement.
Bristol Myers Squibb and Bain Capital announced Monday the creation of a new independent biopharmaceutical company, called NewCo, which will…
Moderna reports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28), and expects 2025 revenue range of $1.5 to 2.5 billion andending cash balance of approximately $6 billion.
CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving pipeline progress PHILADELPHIA, Jan.…
Moderna announced Monday business updates and progress across its pipeline of mRNA medicines, entering 2025 with a focus on a prioritized portfolio addressing respiratory viruses, rare diseases, oncology, and latent and other viruses where there is unmet need, as it achieved $3-3.1B in product sales.
Basilea Pharmaceutica, a Swiss bacterial and fungal infections biopharmaceutical specialist, has entered into an exclusive distribution and license agreement with…
PDUFA goal date is July 27, 2025COPENHAGEN, Denmark, Dec. 12, 2024 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today…